Abstract:Objective Determining the pathogenicity of missense variants in clinical genetic tests for individuals with epilepsy is crucial for guiding personalized treatment. However, achieving a definitive pathogenic classification remains challenging, with most missense variants still classified as variants of uncertain significance (VUS) and with the availability of many computational tools which may provide conflicting predictions. Here, we aim to evaluate the performance of state‐of‐the‐art computational tools in pathogenicity prediction of missense variants in epilepsy‐associated genes. This will assist in selecting the most appropriate tool and critically assess their use in clinical setting. Methods We assessed the performance of nine in silico pathogenicity prediction tools for missense variants in epilepsy‐associated genes on three carefully curated data sets. The first two data sets comprise missense variants in epilepsy associated genes that have been uploaded to ClinVar in the last year and were, therefore, not part of the training set of any of the nine considered tools. These two data sets are based on two different lists of epilepsy‐associated genes and comprise ~700 and ~ 250 missense variants, respectively. The third data set includes ~400 missense variants within epilepsy‐associated genes for which the functional effects have been determined experimentally and are therefore used here to infer pathogenicity. These three data sets represent the best available approximation to blind and independent test sets. Results Among the nine assessed tools, AlphaMissense (area under the curve [AUC]: .93, .88, and .95) and REVEL (AUC: .93, .88, and .93) showed the best classification performance, also outperforming other tools in the number of classified variants. Significance We show which recently developed prediction tools achieve higher performance in epilepsy‐associated genes and should be integrated, therefore, into the American College of Medical Genetics and Genomics/Association of Molecular Pathology (AGMC/AMP) variant classification process. Periodic reevaluation of genetic test results with newly developed or updated tools should be incorporated into standard clinical practice to improve diagnostic yield and better inform precision medicine.

Comparing Sequence-Based and Literature-Based Pathogenicity Scoring Methods for Human Variants

Characterizing the pathogenicity of genetic variants: the consequences of context

Variant scoring performance across selection regimes depends on variant-to-gene and gene-to-disease components

Critical assessment of missense variant effect predictors on disease-relevant variant data

A New Era in Missense Variant Analysis: Statistical Insights and the Introduction of VAMPP-Score for Pathogenicity Assessment

Sequence-Based Prioritization of Nonsynonymous Single-Nucleotide Polymorphisms for the Study of Disease Mutations

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

A Comparison on Predicting Functional Impact of Genomic Variants.

Functional characterization of all missense variants and comparison to in silico models of pathogenicity

Bioinformatics Tools and Databases to Assess the Pathogenicity of Mitochondrial DNA Variants in the Field of Next Generation Sequencing

REVEL: an Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants

AI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

Assessing the function of genetic variants in candidate gene association studies

Evaluating novel in silico tools for accurate pathogenicity classification in epilepsy‐associated genetic missense variants

Performance Comparison of Computational Methods for the Prediction of the Function and Pathogenicity of Non-Coding Variants

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

Comparison of Literature Mining Tools for Variant Classification: Through the Lens of Fifty RYR1 Variants

Major Causes of Conflicting Interpretations of Variant Pathogenicity in Rare Disease: A Systematic Analysis

Guidelines for investigating causality of sequence variants in human disease

VariPred: Enhancing Pathogenicity Prediction of Missense Variants Using Protein Language Models